Free Trial

Josh Schimmer Analyst Performance

Biotech Equity Research Analyst at Cantor Fitzgerald

Josh Schimmer is a stock analyst at Cantor Fitzgerald in the medical sector, covering 24 publicly traded companies. Over the past year, Josh Schimmer has issued 30 stock ratings, including buy and hold recommendations. While full access to Josh Schimmer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Josh Schimmer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
39 Last 8 Years
Buy Recommendations
94.74% 36 Buy Ratings
Companies Covered
24 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy94.7%36 ratings
Hold5.3%2 ratings
Sell0.0%0 ratings

Out of 38 total stock ratings issued by Josh Schimmer at Cantor Fitzgerald, the majority (94.7%) have been Buy recommendations, followed by 5.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
24 companies

Josh Schimmer, an analyst at Cantor Fitzgerald, currently covers 24 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies
100.0%

Josh Schimmer of Cantor Fitzgerald specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
21 companies
87.5%
MED - GENERIC DRG
1 company
4.2%
MED - DRUGS
1 company
4.2%
MEDICAL SERVICES
1 company
4.2%

Josh Schimmer's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
5/11/2026Boost Price Target$11.27$40.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5/4/2026Reiterated Rating$2.94$30.00Overweight
Septerna, Inc. stock logo
SEPN
Septerna
3/10/2026Reiterated Rating$28.61$60.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3/2/2026Reiterated Rating$234.75$324.00Outperform
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2/27/2026Boost Price Target$5.24$10.00Overweight
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2/27/2026Boost Price Target$103.03$140.00Overweight
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2/27/2026Lower Price Target$13.51$100.00Overweight
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
12/18/2025Set Price Target$72.12$72.00
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
12/18/2025Downgrade$72.14Hold
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
12/8/2025Reiterated Rating$67.18$130.00Overweight
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
12/2/2025Lower Price Target$33.99$150.00Overweight
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
11/14/2025Initiated Coverage$5.42Overweight
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
11/6/2025Boost Price Target$79.51$200.00Overweight
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
11/5/2025Boost Price Target$72.38$95.00Overweight
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
11/4/2025Reiterated Rating$39.68$55.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
10/31/2025Boost Price Target$2.72$30.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
10/30/2025Boost Price Target$65.44$110.00Overweight
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
10/29/2025Reiterated Rating$47.98Overweight
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/15/2025Initiated Coverage$84.66$135.00Overweight
Invivyd, Inc. stock logo
IVVD
Invivyd
10/6/2025Initiated Coverage$1.16$10.00Overweight
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
9/22/2025Lower Price Target$42.34$65.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/8/2025Reiterated Rating$32.81$75.00Overweight
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
9/8/2025Reiterated Rating$15.37Overweight
Septerna, Inc. stock logo
SEPN
Septerna
9/5/2025Reiterated Rating$14.44$25.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
9/5/2025Reiterated Rating$1.61$15.00Overweight
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
8/8/2025Lower Price Target$2.90$8.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/29/2025Reiterated Rating$46.59$95.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
7/1/2025Initiated Coverage$5.47$25.00Overweight
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
6/23/2025Reiterated Rating$2.46$6.00In-Line
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/16/2025Boost Price Target$6.50$30.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
5/2/2025Boost Price Target$177.67$280.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
4/28/2025Reiterated Rating$30.06$75.00Overweight
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3/25/2025Lower Price Target$3.92$20.00Overweight
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3/10/2025Initiated Coverage$10.13$50.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/21/2025Reiterated Rating$37.07$95.00Overweight
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2/20/2025Reiterated Rating$187.60$215.00Overweight